Immune response after chemoradiation and immunotherapy for stage III lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how the body’s immune system responds in people with stage III lung cancer (not removable by surgery) who first get chemotherapy and radiation and then receive the immunotherapy drug durvalumab for one year. It aims to learn more about the immune response and why the treatment works better for some people.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IIIA, IIIB, or IIIC non-small cell lung cancer (NSCLC) that cannot be removed with surgery.
- You have completed chemotherapy and radiation together (called cCRT) and your cancer did not get worse.
- Your tumor has a PDL1 score higher than 1%, which means it may respond to immunotherapy.
- You are age 18 or older and your daily activity level is fairly good (able to care for yourself).
- You are about to start or have just started a year of durvalumab (an immunotherapy drug) as your next treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving the immunotherapy drug durvalumab after chemoradiation and surgery helps people with stage 3 non-small cell lung cancer. You will receive standard chemoradiation, then have surgery, and then get durvalumab to see if it lowers the chance of the cancer coming back.
This trial tests a combination of immunotherapy (durvalumab) and chemotherapy before surgery or radiation for people with stage III lung cancer that is on the edge of being removable. The goal is to shrink the tumor enough to allow surgery or more effective radiation.
This trial tests a combination of immunotherapy, chemotherapy, and either surgery or radiation for people with stage IIIA or IIIB non-small cell lung cancer. The goal is to see if adding the drug durvalumab after standard treatment helps control the cancer better.
This trial tests giving durvalumab (an immune therapy) soon after standard chemotherapy and radiation for stage II–III non-small cell lung cancer that cannot be removed by surgery. The goal is to see if this “quick start” approach improves outcomes compared with waiting longer to begin durvalumab.
This trial tests a new combination of chemotherapy, radiation, and immunotherapy (durvalumab) for people with stage III non-small cell lung cancer that cannot be removed with surgery. The goal is to see if giving a smaller, more focused radiation dose can be just as effective with fewer side effects.
This trial tests a new drug, JNJ-90301900, given together with standard chemotherapy and radiation, followed by maintenance immunotherapy (durvalumab) for people with stage 3 non-small cell lung cancer that cannot be surgically removed. The goal is to see if adding this drug improves outcomes.
Hear when a new Non-small Cell Lung Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.